- Home
- XFOR vs NBP Comparison
XFOR vs NBP Comparison
Compare XFOR & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.98
N/A
Current Price
$3.97
Company Overview
Basic Information| Metric | XFOR | NBP |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 370.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | XFOR | NBP |
|---|---|---|
| Price | $3.98 | $3.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $28.50 | N/A |
| AVG Volume (30 Days) | ★ 879.6K | 501.7K |
| Earning Date | 11-05-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,979,000.00 | N/A |
| Revenue This Year | $1,276.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2925.74 | N/A |
| 52 Week Low | $1.35 | $0.60 |
| 52 Week High | $26.83 | $6.79 |
Technical Indicators
Market Signals| Indicator | XFOR | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | N/A |
| Support Level | $3.50 | N/A |
| Resistance Level | $4.56 | N/A |
| Average True Range (ATR) | 0.30 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 47.91 | 0.00 |
Price Performance
Historical Comparison XFOR
NBP
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.